|Day Low/High||124.27 / 125.48|
|52 Wk Low/High||100.34 / 129.70|
The tables have turned, their stocks have been up, and I think they go higher still.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
The Delta virus has more power to control both fiscal and monetary policy than does the data or do any of our leaders individually.
These names have demonstrated over a long period they have the business models and growth prospects to raise their dividend payments each year.
Small-caps and mid-caps are still picking first downs on every play, storming back from a badly oversold condition that has just about normalized.
These names offer appeal to both growth and dividend investors.
Also, the ISM survey results showed us a few trends that at least appear as potential if not troubling question marks on the horizon.
Probably the best news right now is that individual stock picking has improved.
These Dividend Aristocrats have free DRIPs, long histories of raising their dividends, and attractive yields well above the market average.
The technical signals indicate the odds of further weakness in the health care company's shares are low.
Always, always, always stick to your rules. Always. This is why we have targets, pivots and panics.
Microsoft and Abbott Laboratories are the names that are worth watching.
Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.
Traders should continue to hold existing longs on ABT.
Wednesday afternoon the Fed's Federal Open Market Committee will publish the central bank's first official policy statement of 2021.
ABT has made an upside breakout on the daily Point and Figure chart, and here's how investors can make their next move.
Four experts highlight their favorite dividend stocks for 2021.
Maybe we will be better when Covid 2021 comes around. But sustainable? Ha. How about inevitable?
Let's review the charts and indicators.
These companies have spent the last six months preparing for a second lockdown betting it will occur.
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.